EZH2 and cholangiocarcinoma: IL-6 secreted by vCAFs induces increased expression of EZH2 (enhancer of zeste homolog 2) in intrahepatic cholangiocarcinoma cells, driving epigenetic remodeling and thereby enhancing tumor aggressiveness [145].